pCDNA3.1neo-NLucYAP15 Citations (3)

Originally described in: A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis.
Azad T, Janse van Rensburg HJ, Lightbody ED, Neveu B, Champagne A, Ghaffari A, Kay VR, Hao Y, Shen H, Yeung B, Croy BA, Guan KL, Pouliot F, Zhang J, Nicol CJB, Yang X Nat Commun. 2018 Mar 13;9(1):1061. doi: 10.1038/s41467-018-03278-w. PubMed Journal

---

Articles Citing pCDNA3.1neo-NLucYAP15

Articles
Neratinib protects pancreatic beta cells in diabetes. Ardestani A, Li S, Annamalai K, Lupse B, Geravandi S, Dobrowolski A, Yu S, Zhu S, Baguley TD, Surakattula M, Oetjen J, Hauberg-Lotte L, Herranz R, Awal S, Altenhofen D, Nguyen-Tran V, Joseph S, Schultz PG, Chatterjee AK, Rogers N, Tremblay MS, Shen W, Maedler K. Nat Commun. 2019 Nov 1;10(1):5015. doi: 10.1038/s41467-019-12880-5. PubMed
Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma. Slemmons KK, Yeung C, Baumgart JT, Juarez JOM, McCalla A, Helman LJ. Cancer Res. 2020 Jul 15;80(14):3046-3056. doi: 10.1158/0008-5472.CAN-19-3853. Epub 2020 Apr 30. PubMed
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Leung CON, Yang Y, Leung RWH, So KKH, Guo HJ, Lei MML, Muliawan GK, Gao Y, Yu QQ, Yun JP, Ma S, Zhao Q, Lee TKW. Nat Commun. 2023 Oct 23;14(1):6699. doi: 10.1038/s41467-023-42360-w. PubMed

If you have published an article using this material, please email us at to have your article added to this page.